ReviewPharmaceuticals (Basel, Switzerland)2021
Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- A Clinically Grounded Rule-Based Phenotyping Framework for Identifying Immune-Related Adverse Events in Structured Electronic Health Record Data: A Retrospective EHR Study.Research square · 2026Article
- Investigating the repurposing potential of immune checkpoint inhibition for cancer treatment using Mendelian randomisation.Research square · 2026Article
- Ileostoma as a promising tool in pathophysiological study and clinical intervention: a review from bench to beside.Frontiers in immunology · 2026Review
- The Impact of Fecal Diversion on Immune Checkpoint Inhibitor Adverse Gastrointestinal Toxicities.Journal of clinical medicine · 2025Article
- Treatment of immune checkpoint inhibitor-related colitis: a narrative review.Translational cancer research · 2024Review
- Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2024Review
- Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma.International journal of molecular sciences · 2024Article
- New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis.World journal of clinical cases · 2024Review
- Review
- Immunotherapy-induced colitis in metastatic colorectal cancer: a systematic review and meta-analysis.Proceedings (Baylor University. Medical Center) · 2024Article
- Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.BMJ case reports · 2023Article
- The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy.Cancers · 2023Review
- Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.Biomedicines · 2022Review
- Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.Frontiers in cell and developmental biology · 2021Review
- Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, anti-tumor immunotherapies have witnessed a major breakthrough with the emergence of immune checkpoint inhibitors (ICIs). However, the use of ICIs has also brought an era of a certain class of adverse events that differ from those of classical chemotherapies and are more reminiscent of autoimmune diseases. This article focuses exclusively on colitis as an irAE with emphasis on vulnerable patient groups, the prognostic significance of colitis, treatment, and new therapeutic approaches that may be applicable. Colitis itself is associated with a favorable oncological outcome of the underlying disease but is as well the most common irAE leading to discontinuation of therapy. Especially in vulnerable patient groups such as IBD patients and elderly patients, colitis occurs more frequently as a side effect. It is precisely in these two patient groups that side effects more often lead to discontinuation of therapy. Therefore, in addition to the current therapy of colitis through immunosuppression, the focus should also be on new forms of therapy of severe colitis, such as fecal transplantation or ileostomy creation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.